416 related articles for article (PubMed ID: 26133247)
1. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
[TBL] [Abstract][Full Text] [Related]
2. Biomechanical Properties of the Internal Limiting Membrane after Intravitreal Ocriplasmin Treatment.
Vielmuth F; Schumann RG; Spindler V; Wolf A; Scheler R; Mayer WJ; Henrich PB; Haritoglou C
Ophthalmologica; 2016; 235(4):233-40. PubMed ID: 27120551
[TBL] [Abstract][Full Text] [Related]
3. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
[TBL] [Abstract][Full Text] [Related]
4. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
[TBL] [Abstract][Full Text] [Related]
5. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical and ultrastructural evidence of glial cells and hyalocytes in internal limiting membrane specimens of idiopathic macular holes.
Schumann RG; Eibl KH; Zhao F; Scheerbaum M; Scheler R; Schaumberger MM; Wehnes H; Walch AK; Haritoglou C; Kampik A; Gandorfer A
Invest Ophthalmol Vis Sci; 2011 Oct; 52(11):7822-34. PubMed ID: 21900375
[TBL] [Abstract][Full Text] [Related]
7. Lamellar Hole-Associated Epiretinal Proliferation in Comparison to Epiretinal Membranes of Macular Pseudoholes.
Compera D; Entchev E; Haritoglou C; Scheler R; Mayer WJ; Wolf A; Kampik A; Schumann RG
Am J Ophthalmol; 2015 Aug; 160(2):373-384.e1. PubMed ID: 25982970
[TBL] [Abstract][Full Text] [Related]
8. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Results of Vitrectomy for Macular Holes after Failure of Vitreolysis.
Benarous A; Le Mer Y
Ophthalmologica; 2018; 240(1):14-22. PubMed ID: 29566375
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
[TBL] [Abstract][Full Text] [Related]
11. Epiretinal cell proliferation in macular pucker and vitreomacular traction syndrome: analysis of flat-mounted internal limiting membrane specimens.
Zhao F; Gandorfer A; Haritoglou C; Scheler R; Schaumberger MM; Kampik A; Schumann RG
Retina; 2013 Jan; 33(1):77-88. PubMed ID: 22914684
[TBL] [Abstract][Full Text] [Related]
12. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
13. Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
Jeng KW; Baumal CR; Witkin AJ; Witkin SR; Wiegand TW; Waheed NK
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):271-4. PubMed ID: 25707057
[TBL] [Abstract][Full Text] [Related]
14. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
[TBL] [Abstract][Full Text] [Related]
15. ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.
Tadayoni R; Holz FG; Zech C; Liu X; Spera C; Stalmans P
Retina; 2019 Dec; 39(12):2341-2352. PubMed ID: 30308558
[TBL] [Abstract][Full Text] [Related]
16. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology.
Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P
Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990
[TBL] [Abstract][Full Text] [Related]
17. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
[TBL] [Abstract][Full Text] [Related]
19. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
[TBL] [Abstract][Full Text] [Related]
20. Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion.
Kim BT; Schwartz SG; Smiddy WE; Doshi RR; Kovach JL; Berrocal AM; Moshfeghi AA; Fortun JA
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(4):334-43. PubMed ID: 23883268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
